Review anchor
Acetylcholine receptor subunit epsilon
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Acetylcholine receptor subunit epsilon
CHEMBL2484
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Acetylcholine receptor subunit epsilon as ChEMBL target CHEMBL2484, mapped to UniProt Q04844. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL2484
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q04844
Acetylcholine receptor subunit epsilon
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Acetylcholine receptor subunit epsilon matters
Acetylcholine receptor subunit epsilon is reviewed as Acetylcholine receptor subunit epsilon (UniProt Q04844); the current evidence base includes 3 approved drugs, 81 compounds, and 18 assays, with lead potency reaching pChEMBL 8.6.
Protein context
Acetylcholine receptor subunit epsilon
Acetylcholine receptor subunit epsilon Sequence length is 493 aa.
Review this target as Acetylcholine receptor subunit epsilon, mapped to UniProt Q04844. Sequence length is 493 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q04844
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 3 approved drugs, 81 compounds, and 18 assays for this target. The dominant activity type is IC50. CHEMBL5179810 is the current potency anchor at pChEMBL 8.6.
Use CHEMBL5179810 as the tractability anchor when discussing potency (pChEMBL 8.6).
Activity source · ChEMBL 36 via Core Engine
3 approved
pChEMBL 8.6
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Acetylcholine receptor subunit epsilon matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q04844, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
81
Total Compounds
18
Total Assays
3
Approved Drugs
IC50: 42.0, KI: 3.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL5179810
|
8.6 | IC50 | — |
|
|
No preferred name
CHEMBL4473371
|
8.5 | Ki | — |
|
|
No preferred name
CHEMBL4435544
|
8.2 | IC50 | — |
|
|
No preferred name
CHEMBL5204683
|
7.9 | IC50 | — |
|
|
No preferred name
CHEMBL4471876
|
7.6 | IC50 | — |
Source Header